
Small molecules continue to 🤯
This MoA will blow your mind! Amazing what small molecules are able to do. This one suggests novel future capabilities and applications.


Small molecules continue to 🤯
This MoA will blow your mind! Amazing what small molecules are able to do. This one suggests novel future capabilities and applications.

Take a look and share your thoughts on what other indications we are missing. a16z.com/outclassed-the-batt…

Here, @JorgeCondeBio , @adelatomsejova , and I dove into a case study on the ongoing battle for market share in the SMA landscape to ask how patients, clinicians, and the market ultimately determine what counts as "best-in-class".

Understanding these market dynamics is crucial for making decisions in highly evolving therapeutic areas. We anticipate these modality battles to continue and are already seeing them play out in indications like SMA, hypercholesterolemia, ATTR Amyloidosis, and AAT deficiency

Biotech has seen a surge in the development of new modalities in recent years. At a16z bio+health, we spend a lot of time thinking about how new modalities fit into increasingly crowded indication landscapes.

Welcome, Greg! Thrilled to be working with you!
Join us in welcoming Dr. Greg Verdine as a16z Bio + Health Venture Partner! With a record of academic leadership, innovative drug discovery & serial entrepreneurial success in biotech, he's a game-changer. More from @vintweeta + @JorgeCondeBio here: a16z.com/2023/07/20/greg-ver…

New @a16zBioHealth Bio Eats World Journal Club episode is out! I had a wonderful time discussing the @Majzner_Lab's new work engineering CAR T cells with true boolean logic gates for improved safety and efficacy. Thanks to Robbie for joining. Listen in! 🎧 bio-eats-world.simplecast.co…

Thrilled to be part of this years team and the opportunity to make an impact on such an important cause! Please consider donating: justgiving.com/fundraising/b…
The #TimmermanTraverse is back! @ldtimmerman is leading 20+ industry leaders up and over 7 mountain peaks to grow support for our programs & partnerships. Learn more: lifesciencecares.org/news/20… @LS_CaresSD @LS_CaresPhilly

In 2020, before she won the @NobelPrize in chemistry, @CarolynBertozzi sat down with Bio Eats World to discuss her work on lysosome-targeting chimeras, which break down proteins gone haywire. In honor of her win, check out our re-released episode 👇 podcasts.apple.com/us/podcas…

Thrilled to be part of Orbital Tx!! @a16z biohealth
1/ "In the history of medicine, certain therapeutic classes have revolutionized the treatment of both prevalent and rare diseases, and RNA-based therapeutics is undoubtedly one of them.” -- @gciaramella1 Excited for the launch of Orbital Tx today! businesswire.com/news/home/2…

Cocktail therapies—combos of drugs that attack different parts of a virus—made HIV a manageable condition. Can we use precision cocktails to fight cancer? IDRx aims to punch back against cancer through intelligently designed combination therapies. 🥊🥊🥊 a16z.com/2022/08/02/investin…

Today @FlagshipPioneer announced the close of a $3.4 billion capital pool that will enable us to accelerate the creation and growth of our next-generation bioplatform companies. flagshippioneering.com/press…

How can we prepare for the next pandemic? Flagship's Lovisa Afzelius and Alex Goldsmith explain the imperative for a Global Pathogen Shield, focused on discovery, surveillance, and prognostic readiness tools and approaches. @afzelius_lovisa flagshippioneering.com/stori…


What makes this the #biotechmoment, and what gives all of us in the field - scientists, entrepreneurs, investors - permission to leap to unexplored places in search of bold new breakthroughs? My thoughts here: flagshippioneering.com/stori…
